SEARCH

SEARCH BY CITATION

References

  • 1
    Gane E, Portmann B, Naoumov N et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.DOI: 10.1056/NEJM199603283341302
  • 2
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 3
    Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 67384.
  • 4
    Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642650.DOI: 10.1053/gast.2003.50095
  • 5
    Terrault N. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl 2003; 9S959S100.DOI: 10.1053/jlts.2003.50255
  • 6
    Reddy K, Wippler D, Zervos X et al. Recurrent HCV infection following liver transplantation: The role of early post transplant interferon treatment. Hepatology 1996; 24(4 Pt 2): 295A.
  • 7
    Singh N, Gayowski T, Wannstedt CF et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial. Transplantation 1998; 65(1): 826.DOI: 10.1097/00007890-199801150-00016
  • 8
    Sheiner P, Boros P, Klion F et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831838.DOI: 10.1002/hep.510280334
  • 9
    Mazzaferro V, Regalia E, Pulvirenti A et al. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant Proc 1997; 29: 519521.DOI: 10.1016/S0041-1345(96)00248-5
  • 10
    Mazzaferro V, Tagger A, Schiavo M et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 13551357.DOI: 10.1016/S0041-1345(00)02508-2
  • 11
    McHutchison J, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response to genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10611069.DOI: 10.1053/gast.2002.35950
  • 12
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.DOI: 10.1056/NEJMoa020047
  • 13
    Talal A, Weisz K, Hau T, Kreiswirth S, Dieterich D. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol 2001; 96: 28022804.
  • 14
    Gergely A, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002; 35: 12811282.DOI: 10.1053/jhep.2002.32529
  • 15
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958965.DOI: 10.1016/S0140-6736(01)06102-5
  • 16
    Shiffman ML, Di Bisceglie A, Lindsay KL et al. PegInterferon alfa-2a and ribvarin in patients with chronic hepatitis C who have failed prior treatment. Gasteroenterology 2004; 126: 10151023.DOI: 10.1053/j.gastro.2004.01.014
  • 17
    Jain A, Eghtesad B, Venkataramanan R et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8: 10071013.DOI: 10.1053/jlts.2002.36241
  • 18
    Menon K, Poterucha J, El-Amin OM et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons in tolerability and efficacy. Liver Transpl 2002; 8: 623629.DOI: 10.1053/jlts.2002.33968
  • 19
    Shakil AO, McGuire B, Crippin J et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 12531258.DOI: 10.1053/jhep.2002.36162
  • 20
    Rostaing L, Chatelut E, Payen J et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 1998; 9: 23442348.
  • 21
    Gotoh A, Hara I, Fujisawa M et al. Pharmacokinetics of natural human IFN-alpha in hemodialysis patients. J Interferon Cytokine Res 1999; 19: 11171123.DOI: 10.1089/107999099313055
  • 22
    Tan A, Brouwer J, Glue P et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study. Nephrol Dial Transplant 2001; 16: 193195.DOI: 10.1093/ndt/16.1.193
  • 23
    Manns M, McHutchison J, Gordon S et al. PegInterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958965.DOI: 10.1016/S0140-6736(01)06102-5
  • 24
    Dieterich D, Wasserman R, Brau N et al. Once weekly epoetin alfa improves anemia and facilitates maintenance of riabivirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 24912499.